Saw this pr thought this might be of interest .
(COMTEX) B: NATIONAL HEALTH & SAFETY SIGNS EXCLUSIVE MARKETING RIGHTS
B: NATIONAL HEALTH & SAFETY SIGNS EXCLUSIVE MARKETING RIGHTS FOR NEW DIAGNOSTIC
Utrasound Technology
WARMINSTER, Pa., Dec. 2 /PRNewswire/ -- National Health & Safety
Corporation (OTC Bulletin Board: NHLT) announced today that it has
signed an exclusive licensing agreement to market a new diagnostic
ultrasound technology to its national network of hospitals and doctors
in North America.
The new technology, owned and manufactured by Longport, Inc. of
Swarthmore, PA (OTC Bulletin Board: LPTI), includes a soft tissue
scanning device with which the Longport scanner can identify tiny soft
tissue abnormalities such as melanomas within the skin and up to 1.5
inches under it without the need for invasive procedures such as
biopsies.
Dr. Dennis Bowers, CEO of National Health & Safety, described the soft
tissue scanner as a "major medical breakthrough" with the potential to
save hundreds of thousands of lives.
Earlier this month, clinical studies commenced at Thomas Jefferson
University Hospital in Philadelphia, PA, which will test the ability of
the soft tissue scanner to detect and diagnose "satellite" locations of
cancer cells which are often missed in some kinds of cancer surgical
procedures, especially melanomas. The clinical studies are under the
scientific direction of Dr. Levon Nazarian and Dr. Barry Goldberg at
Thomas Jefferson University. National Health & Safety is underwriting
the cost of the study.
Satellite locations are very tiny, often no larger than the head of a
pin, and may be missed in surgery. They can spread undetected through
the body until it is too late to treat them successfully.
"This technology is so important that we expect the vast majority of
our 3,300 hospitals and many of our 360,000 doctors and surgeons to
utilize the technology during the next two years," Bowers said. He
estimated that revenues generated by use of the Longport technology
could exceed $100 million by the end of the third year of marketing.
In addition, the Longport technology has many other applications. These
include monitoring the development and healing of wounds such as
bedsores, burns, and diabetic ulcers, the detection of residual metal
fragments in Veterans and steelworkers, applications in dentistry,
sports medicine and veterinary sciences.
National Health & Safety has committed several millions of dollars to
the continued development, manufacturing and marketing of the Longport
technology during the next two years. Bowers indicated that the
exclusive North American marketing rights to the technology is expected
to deliver a high return on the investment of NHS.
National Health & Safety is America's first national medical discount
network, with more than 700,000 medical, surgical and other providers
participating nationwide. The POWERx network includes more than 70% of
the nation's doctors, surgeons, and hospitals, and more than 90% of the
nation's pharmacies. Trade-named the POWERx Medical Benefits Network,
any company or individual can obtain access to the network providers
for about $200 per year. Company employees can then obtain services and
products from the providers at discounts of up to 60%.
The Longport scanner is the first of several breakthrough medical
devices which National Health & Safety plans to make available to is
network providers under a new division of the company named ACCESS
Advantage. Bowers said that National Health & Safety is presently under
discussions with other manufacturers of new technology to obtain
exclusive licensing rights similar to the one with Longport, which it
will also make available to its network of health care providers.
The Longport scanner was recently selected as one of the important new
medical breakthroughs in a Public Television Special presented by
American Medical Review, which was narrated by Charlton Heston and
distributed to 320 Public Television stations nationwide.
Studies of the Longport scanner are currently ongoing at West Jersey
Medical Center in Camden, NJ, West Hudson Hospital in Kearny, NJ, and
Guy's and St. Thomas' Hospitals in London. Approval of the new scanner
for soft tissue applications is expected to be received from the Food
and Drug Administration (FDA) sometime during the first half of 1999,
after which marketing will begin.
SOURCE National Health & Safety Corporation
-0- 12/02/98 /CONTACT: Kerri A. Millar of
National Health & Safety, 215-442-0926/
(NHLT LPTI)
CO: National Health & Safety Corporation; Longport, Inc. ST:
Pennsylvania IN: HEA MTC SU: LIC
*** end of story ***
|
